ALBUQUERQUE, N.M.--(BUSINESS WIRE)--Cancer diagnostics company Biomoda, Inc. (OTCBB: BMOD) (www.biomoda.com) has selected RCRI, Inc. to be the Contract Research Organization (CRO) for the upcoming pivotal clinical trial of the CyPath® diagnostic for early detection of lung cancer.
